T 1475/16 of 07.02.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T147516.20220207
- Date of decision
- 7 February 2022
- Case number
- T 1475/16
- Petition for review of
- -
- Application number
- 03761744.6
- IPC class
- C07H 19/23C07H 19/14C07H 19/052C07H 19/22C07H 19/06C07H 19/20A61K 31/7056C07H 19/12C07H 19/056A61K 31/7064A61P 31/14C07H 19/10C07H 19/04C07H 19/048A61K 31/706C07H 19/044C07H 19/16
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- MODIFIED 2' AND 3' -NUCLEOSIDE PRODUGS FOR TREATING FLAVIRIDAE INFECTIONS
- Applicant name
- Idenix Pharmaceuticals LLC
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS-
UNIVERSITA' DEGLI STUDI DI CAGLIARI
Université de Montpellier
Idenix SARL - Opponent name
- Gilead Sciences, Inc.
Wiegeleben, Peter
F.Hoffmann-La Roche AG
Strawman Limited
Wächtershäuser & Hartz
Patentanwaltspartnerschaft mbB - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(2)
- Keywords
- Basis of decision - text or agreement to text withdrawn by patent proprietor
- Catchword
- -
- Cited cases
- T 1021/15
- Citing cases
- -
Order
For these reasons it is decided that:
The appeal is dismissed.